Dermatological Disorders

MPR Weekly Dose Podcast Episode 94

The Pfizer-BioNTech COVID-19 vaccine gets Emergency Use Authorization for booster doses in certain individuals; A smaller vaccine dose appears safe and effective in children; A survey sheds light on parents’ thoughts on child COVID vaccination; Janssen share booster data for their vaccine; Remdesivir efficacy data in COVID-19 patients, And Opzelura is approved for atopic dermatitis.

Clinical Challenge: Itchy Rash on Infant

A 5-month-old Hispanic infant presents for evaluation of a rash involving his arms and trunk that has worsened over the past month. Can you make the correct diagnosis?

Opzelura Cream Approved for Atopic Dermatitis

The Food and Drug Administration has approved Opzelura (ruxolitinib) cream for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. The approval was based on data…